Inuvair

Formoterol fumarate dihydrate / beclometasone dipropionate anhydrous, the active ingredient in Inuvair, is a LABA/ICS combination presented as an inhaler for inhalation use. It provides maintenance therapy for asthma and chronic obstructive pulmonary disease in adults.

GNH USA supplies Inuvair as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inuvair is a fixed‑dose inhaled combination that targets airway obstruction and inflammation in chronic respiratory disease. - Asthma: improves symptom control and reduces the frequency of exacerbations. - Chronic obstructive pulmonary disease (COPD): enhances lung function and lowers the risk of COPD flare‑ups. - Maintenance therapy: provides long‑term bronchodilation and anti‑inflammatory effect for patients requiring daily inhaled treatment.

Adverse reactions may occur with inhaled therapy and should be monitored.

Common Side Effects: - Throat irritation or soreness. - Cough or wheeze after inhalation. - Hoarseness or voice changes. - Oral candidiasis (thrush). - Headache. - Tremor or shakiness.

Serious or Rare Side Effects: - Paradoxical bronchospasm. - Severe allergic reaction (anaphylaxis). - Cardiac arrhythmia or palpitations. - Pneumonia, especially in COPD patients. - Adrenal suppression with high‑dose or prolonged use. - Reduced bone mineral density with chronic exposure.

Before prescribing Inuvair, clinicians should consider several safety aspects. - Assess disease control: confirm that the patient requires combination therapy. - Monitor for oral thrush: advise rinsing mouth after each inhalation. - Use a spacer device: helps reduce oropharyngeal deposition. - Avoid abrupt discontinuation: taper if long‑term use is planned. - Evaluate cardiovascular risk: caution in patients with arrhythmias or hypertension. - Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Inhaled corticosteroid/LABA combinations can interact with other medicines that affect the respiratory or cardiovascular systems.

Major Interactions (Avoid): - Non‑selective beta‑blockers: may blunt bronchodilator effect. - Potent CYP3A4 inhibitors (e.g., ketoconazole): can increase systemic exposure to beclometasone. - Monoamine oxidase inhibitors (MAOIs): may enhance sympathomimetic activity.

Moderate Interactions (Monitor Closely): - Diuretics: may exacerbate hypokalaemia when combined with β2‑agonists. - Theophylline: additive bronchodilator effect may increase side‑effects. - Other inhaled corticosteroids: risk of systemic glucocorticoid effects. - Sympathomimetic agents (e.g., epinephrine): may increase cardiovascular stimulation.